On October 1, 2024, Howard Welgus, Director at Arcutis Biotherapeutics Inc (ARQT, Financial), executed a sale of 10,000 shares of the company. The transaction was filed on the same day with the SEC. Following this sale, the insider now owns 181,944 shares of Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. The company's innovative approach targets specific pathways to address various skin conditions.
The shares were sold at a price of $9.26, valuing the transaction at approximately $92,600. This sale is part of a broader trend observed over the past year, where the insider has sold a total of 50,000 shares. Notably, the insider has not made any share purchases during this period.
The broader insider transaction history for Arcutis Biotherapeutics Inc shows a predominance of sales over purchases. In the past year, there have been 23 insider sales and only 2 insider buys. This trend can be visualized in the following insider trend image:
On the valuation front, the recent trading price of $9.26 gives Arcutis Biotherapeutics Inc a market cap of approximately $1.19 billion. Investors may also explore various valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow to gain a deeper understanding of the stock's current valuation.
This insider sale could be of interest to current and potential investors, providing insights into insider confidence and potential future stock performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
